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ABSTRACT The aim of this study was to investigate the effects of a-adrenergic antagonists 
on the motor activity of the postpartum uterus of the rat in vivo. Intrauterine pressure was 
assessed by means of a Millar catheter fitted with a latex microballoon. Some of the tested 
compounds (urapidil, yohimbine, phentolamine, benoxathian and prazosin) decreased the 
uterine activity to a significant extent (57467.4%). However, none of the investigated o- 
receptor blockers exerted the same effect as P-adrenergic agonists. Our results uggest that CL- 
adrenergic antagonists could possibly be used as an alternative to P-adrenergic agonists in 
. . 
clinical tocolysis after an appI'OpIate chcd eValUatl0I-t. Q 1997 Elsevier Science lnc. 
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Introduction 
Premature labor is one of the main causes of perinatal death in the developed countries 
(1). The authorized choice for the treatment of premature labor includes P-adrenergic agonists 
and magnesium sulfate. The latter is not so frequently used in Europe at present. The other 
disadvantage to the use of magnesium sulfate for tocolysis is the lack of an effective oral 
dosage form for maintenance use. As regards the p-adrenergic agonists, there are numerous 
clinical situations (e.g. tachycardia, diabetes mellitus and arrhythmias) where these drugs are 
contraindicated. Such data indicate that tocolysis is not a solved clinical problem. Many 
examples can be cited of the opposite ffect, i.e. of physiological processes mediated by CL- 
and P-adrenergic receptors. Since Garrett demonstrated this relation for the case of the human 
myometrium (2), it has been concluded that the a-adrenergic receptor antagonists may have a 
similarly beneficial effect to that of p-agonists on the uterine activity. However, the published 
data in support of this theory are at present very limited. Lechner et al. investigated the effect 
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of doxazosin on human isolated myometrial strips and suggested that a-blockade could be a 
logical substitution for p-stimulation (3). A bolus dose of prazosin administered at midday on 
day 22 completely blocks the normal process of the parturition of the rat throughout the next 6 
h. Administration of phentolamine at term induced a significant decrease of the uterine 
activity of the rat in vivo (4). Palop et al. demonstrated that prazosin abolished the 
methoxamine-induced increase of the uterine motility of the rat (5). Ko et al. found that 
xylazine, a selective o?*-adrenergic agonist, was able to enhance the porcine myometrial 
contractility in vitro and this effect was antagonized by yohimbine in a dose-dependent 
manner (6). 
The objective of the present study was a comparative investigation of the inhibitory 
effects of cL-adrenergic receptor antagonists, including cq and 01~ subtype-selective 
compounds, on the uterine motor activity. A reliable method was elaborated which is suitable 
for testing drugs acting on the uterine activity in vivo. The effects of eight a-antagonists were 
investigated on the spontaneous uterine activity of the postpartum rat. 
Methods 
Female Sprague-Dawley rats were anaesthetized with urethane (1 g/kg, i.p.) 8-12 h 
after spontaneous delivery. After cannulation of the jugular vein, the abdominal cavity was 
opened and a Millar catheter fitted with a latex microballoon was inserted into the uterus 
through a small section above the cervical part. The intrauterine pressure was recorded 
(Hewlett-Packard 7702B) and the effects of the drugs were assessed by expressing the 
integrated tension in the l-6 min. period after administration of each compound as a 
percentage of the average for three 5-min. periods before administration. The maximal 
inhibition and ED,, value were calculated by means of Graft 3.01. 
The following drugs were diluted with physiological saline: phentolamine (Ciba-Geigy 
AG, Switzerland), urapidil (Byk Gulden, Germany), fenoterol (Boehringer Ingelheim, 
Germany), terbutalin (Egis-Astra, Hungary), CH-38083 (Chinoin, Hungary), BRL-41992 and 
BRL-44408 (SmithKline Beecham, U.K.), benoxathian (a gift from Prof. C. Melchiorre, Dept. 
of Chemical Sciences, University of Camerino, Italy), prazosin and yohimbine (Sigma- 
Aldrich Ltd., Hungary). The final dilutions of the BRL compounds contained 0.01% 
hydrochloric acid. 
Results 
All of the tested compounds decreased the spontaneous uterine activity in a dose- 
dependent manner (Table 1). In spite of the fact that no significant difference was found 
between the effectivities of phentolamine, prazosin, yohimbine, urapidil and benoxathian, on 
the basis of the calculated values the most effective and most potent a-receptor blocking agent 
was prazosin. The non-selective a-antagonist phentolamine, the q-blocker urapidil, the cr2- 
blocker yohimbine and the ai_&- selective antagonist benoxathian were similarly effective, but 
slightly less potent. The $A and aZB -selective antagonists (BFU-44408 and BRL41992, 
respectively) and the non-selective cr,-blocker CH-38083 had only limited effects (7, 8). To 
compare the inhibitory effects of cr-blocking agents with those of traditionally used tocolytics, 
we examined fenoterol and terbutalin in the same in viva system. Both had a higher efficacy 
and a much lower ED,, value (Fig. 1). 
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TABLE I 
Calculated ED,, and maximal inhibition values of the tested compounds 
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Fig. 1 
Inhibition of spontaneous uterine activity of the rat by fenoterol (B), 
prazosin (+), yohimbine (*), phentolamine (0) and CH-38083 (Cl). 
The data are the averages of the results from six experiments f S.E.M. 
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Discussion 
In spite of the obvious hormonal differences between the postpartum rat and the 
human situation, this preparation can be regarded as an animal model of pregnancy (9). 
Agents affecting the human pregnant uterus exert a similar effect on this object. The novelty 
in our method is the application of a Millar catheter fitted with a latex microballoon, which 
makes the measuring more precise. Our results clearly demonstrate that a-adrenergic 
antagonists have a potential tocolytic effect. Five of the eight tested a-blockers decreased the 
uterine activity to a significant extent. The question arises of whether the relaxant effect of the 
tested a-receptor blockers is a consequence of the decreased blood pressure, or whether they 
have a direct effect on the uterus. We carried out experiments on isolated uterus from the rat 
(unpublished data), and found similar results. Moreover, the a*-blocker yohimbine increases 
the blood pressure, but decreases the motor activity of the uterus of the rat. These data support 
the theory that a-blockers have a direct relaxing effect on the myometrium. Since the effects 
of both 01~ and a,-adrenergic receptors are at least partly mediated by a calcium current, it is 
possible that these agents exert their tocolytic effect not only on the a-adrenergic receptor, but 
also on the calcium channel (10, 11). On the other hand, some of the calcium channel blockers 
(e.g. nifedipine) are under clinical investigation as tocolytics (1). From these facts we 
conclude that an a-antagonist which has a definite calcium channel blocking activity (e.g. 
monatepil) may have a higher tocolytic potency and/or efficacy than those of prazosin. None 
of the tested drugs were as potent and effective as fenoterol and terbutalin. However, there are 
special groups of patients (e.g. with pregnancy-induced hypertension, tachycardia, diabetes 
and arrhythmia) where these o-receptor blockers, and in particular prazosin and its congeners, 
might be preferred to traditionally used l@ympathomimetics. Our results may encourage 
further scientific input into the development of highly subtype-selective (myometrium- 
specific) a-blockers as clinically usable tocolytics. As concerns the rank order of efficacy of 
the tested a-blockers, it is suggested that CQ subtype-selective antagonists might be the most 
reliable agents. On the basis of these animal experiments, a well-controlled clinical trial could 
be recommended for an evaluation of the uterus-relaxing effect of the currently used CL- 
blockers. 
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